{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=58&sponsor=AstraZeneca",
    "query": {
      "sponsor": "AstraZeneca",
      "page": 58
    },
    "page_size": 10
  },
  "pagination": {
    "page": 58,
    "page_size": 10,
    "total_count": 1904,
    "total_pages": 191,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=59&sponsor=AstraZeneca&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=57&sponsor=AstraZeneca&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T15:14:44.126Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00014690",
      "title": "ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "plevitrexed",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2001-03",
      "completion_date": "2004-02",
      "has_results": false,
      "last_update_posted_date": "2013-08-02",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014690"
    },
    {
      "nct_id": "NCT02780713",
      "title": "A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AZD9496 (Reference)",
          "type": "DRUG"
        },
        {
          "name": "AZD9496 Variant A",
          "type": "DRUG"
        },
        {
          "name": "AZD9496 Variant B",
          "type": "DRUG"
        },
        {
          "name": "AZD9496 Variant C",
          "type": "DRUG"
        },
        {
          "name": "AZD9496 Variant D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2016-06-02",
      "completion_date": "2016-09-20",
      "has_results": true,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780713"
    },
    {
      "nct_id": "NCT01030224",
      "title": "This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AZD9742",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match AZD9742",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "23 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2009-11",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2012-07-27",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01030224"
    },
    {
      "nct_id": "NCT03923270",
      "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer Extensive Stage",
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Olaparib Pill",
          "type": "DRUG"
        },
        {
          "name": "Thoracic Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2019-06-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03923270"
    },
    {
      "nct_id": "NCT03433183",
      "title": "SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Peripheral Nerve Sheath Tumors",
        "Neurofibromatosis 1"
      ],
      "interventions": [
        {
          "name": "Selumetinib",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarcoma Alliance for Research through Collaboration",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-10-02",
      "completion_date": "2023-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 5,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03433183"
    },
    {
      "nct_id": "NCT05403723",
      "title": "Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extensive-stage Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab 50 MG/1 ML Intravenous Solution",
          "type": "DRUG"
        },
        {
          "name": "Etoposide Injection",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiotherapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2027-01-30",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05403723"
    },
    {
      "nct_id": "NCT00274469",
      "title": "A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "anastrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 100 Years · Female only"
      },
      "enrollment_count": 205,
      "start_date": "2006-02-06",
      "completion_date": "2017-01-13",
      "has_results": true,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 5,
      "location_summary": "Frederick, Maryland • St Louis, Missouri • Teaneck, New Jersey + 2 more",
      "locations": [
        {
          "city": "Frederick",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Duncanville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274469"
    },
    {
      "nct_id": "NCT03638141",
      "title": "CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intermediate Stage of Hepatocellular Carcinoma",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-10-02",
      "completion_date": "2024-08-20",
      "has_results": true,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03638141"
    },
    {
      "nct_id": "NCT07611110",
      "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Deutenzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Radium-223",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 670,
      "start_date": "2026-05-04",
      "completion_date": "2030-06-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 28,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07611110"
    },
    {
      "nct_id": "NCT05047172",
      "title": "Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intracranial Arteriosclerosis",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Ticagrelor + Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban + Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel + Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Risk Factor Management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 1683,
      "start_date": "2022-08-02",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-04T15:14:44.126Z",
      "location_count": 114,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05047172"
    }
  ]
}